Clinical profile of Valette®
article
OA: closed
CC0
AI-generated summary
Valette®, a combination of ethinylestradiol and dienogest, reliably inhibited ovulation and reduced endometrial thickness while exhibiting balanced procoagulatory and fibrinolytic effects on the hemostatic system.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Studies have been undertaken to investigate the modulatory effects of a combination of 30 μg ethinylestradiol and 2.00 mg dienogest (Valette®) on ovarian function and on the hemostatic system. Modulation of ovarian function was investigated by hormone assays and ultrasonography. Effects on the hemostatic system were investigated in a double-blind, randomized, placebo-controlled study. In the ovulation inhibition study, none of the subjects had ovulatory cycles, and only one subject in the first cycle (4%) showed active follicle-like structures. Endometrial thickness was reduced to less than 10 mm. It was noted that Valette had a balanced effect on the hemostatic system, stimulating both procoagulatory and fibrinolytic activities. The present data combine to show that Valette is a reliable ovulation inhibitor with an efficacy comparable to other low-dose preparations.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest 1997
- Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system 1997
- Der Einfluß von Dienogest auf die Ovulation junger Frauen und auf weitere ausgewählte endokrinologische Parameter 1995
References (22)
- Der Einfluß von Dienogest auf die Ovulation junger Frauen und auf weitere ausgewählte endokrinologische Parameter via openalex
- Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system via openalex
- Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest via openalex
- doi:10.1016/0010-7824(96)00137-0 via openalex
- doi:10.1016/0002-9378(90)90590-4 via openalex
- doi:10.1016/s0140-6736(80)91550-0 via openalex
- doi:10.1016/0010-7824(95)00271-5 via openalex
- doi:10.1016/s0002-9378(16)32484-x via openalex
- doi:10.1016/s0002-9378(87)80129-1 via openalex
- doi:10.1136/bmj.280.6224.1157 via openalex
- doi:10.1007/bf01986524 via openalex
- doi:10.1016/0010-7824(85)90072-1 via openalex
- doi:10.1136/bmj.2.5704.293 via openalex
- doi:10.1016/0010-7824(95)00228-6 via openalex
- doi:10.1016/0010-7824(94)90106-6 via openalex
- W2186866099 via openalex
- W2300692921 via openalex
- doi:10.1016/s0010-7824(96)00183-7 via openalex
- doi:10.1007/978-3-642-73790-9_8 via openalex
- doi:10.1007/s40278-026-93643-1 via openalex
- doi:10.1016/0002-9378(90)90596-y via openalex
- doi:10.1136/bmj.1.5690.231 via openalex
Source provenance
- openalex
- last seen: 2026-05-10T11:17:36.253347+00:00
License: CC0
· commercial use OK